Terms: = Thyroid cancer AND NT5C2, ENSG00000076685, 22978, P49902, PNT5, NT5B, GMP, cN-II
11 results:
1. Activatable Mn
Liang Q; Chen J; Hou S; Li D; Zhu Y; Li R; Chen L; Li J; Fu W; Lei S; Zhang B; Zheng X; Zhang T; Duan H; He W; Ren J
Biomaterials; 2023 Sep; 300():122206. PubMed ID: 37348325
[TBL] [Abstract] [Full Text] [Related]
2. A Brief Review of Radioactive Materials for Therapeutic and Diagnostic Purposes.
Bharti M; Alam MA; Rao GSNK; Sharma PK
Curr Radiopharm; 2023; 16(1):23-37. PubMed ID: 36306460
[TBL] [Abstract] [Full Text] [Related]
3. Novel TMEM173 Mutation and the Role of Disease Modifying Alleles.
Keskitalo S; Haapaniemi E; Einarsdottir E; Rajamäki K; Heikkilä H; Ilander M; Pöyhönen M; Morgunova E; Hokynar K; Lagström S; Kivirikko S; Mustjoki S; Eklund K; Saarela J; Kere J; Seppänen MRJ; Ranki A; Hannula-Jouppi K; Varjosalo M
Front Immunol; 2019; 10():2770. PubMed ID: 31866997
[TBL] [Abstract] [Full Text] [Related]
4. Determining the molecular test for indeterminate thyroid nodules best suited for our practice: A quality assurance study.
Maerki J; Klein M; Chau K; Gimenez C; Fishbein J; Khutti S; Das K
Diagn Cytopathol; 2019 Apr; 47(4):259-267. PubMed ID: 30488606
[TBL] [Abstract] [Full Text] [Related]
5. Determining Patient Preferences for Indeterminate thyroid Nodules: Observation, Surgery or Molecular Tests.
Lee DJ; Xu JJ; Brown DH; Gilbert RW; Gullane PJ; Irish JC; Rotstein LE; Goldstein DP; de Almeida JR
World J Surg; 2017 Jun; 41(6):1513-1520. PubMed ID: 28175931
[TBL] [Abstract] [Full Text] [Related]
6. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology.
Lee L; How J; Tabah RJ; Mitmaker EJ
J Clin Endocrinol Metab; 2014 Aug; 99(8):2674-82. PubMed ID: 24684467
[TBL] [Abstract] [Full Text] [Related]
7. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study.
Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M
J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508
[TBL] [Abstract] [Full Text] [Related]
8. High activity of cyclic 3',5'-nucleotide phosphodiesterase in sera of patient with phaeochromocytoma.
Nakai A; Nagasaka A; Ohyama T; Aono T; Iwase K; Hasegawa H; Hayami S; Hidaka H; Tanaka T; Niinomi M
Clin Endocrinol (Oxf); 1986 Apr; 24(4):409-14. PubMed ID: 3017609
[TBL] [Abstract] [Full Text] [Related]
9. Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Nagasaka A; Hasegawa H; Hayami S; Hidaka H; Tanaka T; Niinomi M; Nihei N; Nakagawa H; Ohyama T; Aono T
Enzyme; 1985; 33(1):18-24. PubMed ID: 2985379
[TBL] [Abstract] [Full Text] [Related]
10. Thyrotrophin stimulation of adenylate cyclase and iodine uptake in human differentiated thyroid cancer.
Thomas-Morvan C; Carayon P; Schlumberger M; Vignal A; Tubiana M
Acta Endocrinol (Copenh); 1982 Sep; 101(1):25-31. PubMed ID: 7124290
[TBL] [Abstract] [Full Text] [Related]
11. Human thyroid cyclic nucleotide phosphodiesterase. Its characterization and the effect of several hormones on the activity.
Nagasaka A; Hidaka H
Biochim Biophys Acta; 1976 Jul; 438(2):449-60. PubMed ID: 182233
[TBL] [Abstract] [Full Text] [Related]
